The Role of Diagnostic Imaging in the Planning and Evaluation of Ablation Techniques

  • Ashraf Thabet
  • Debra A. Gervais


The role of pre- and posttreatment imaging in thermal ablation of liver, renal, and lung tumors is reviewed. Typical imaging features on CT, MRI, and PET of successful treatment, viable tumor, and benign ancillary findings that may be confused with viable tumor are discussed. Imaging features of complications of ablation are also considered.


Positron Emission Tomography Renal Cell Carcinoma Viable Tumor Thermal Ablation Ablation Zone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Thabet A, Kalva S, Gervais D. Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. Abdom Imaging. 2009;34:593–609.PubMedCrossRefGoogle Scholar
  2. 2.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer. 2001;88:2452–63.CrossRefGoogle Scholar
  4. 4.
    Sironi S, Livraghi T, Meloni F, et al. Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. AJR Am J Roentgenol. 1999;173:1225–9.PubMedGoogle Scholar
  5. 5.
    Merkle EM, Nour SG, Lewin JS. MR imaging follow-up after percutaneous radiofrequency ablation of renal cell carcinoma: findings in 18 patients during first 6 months. Radiology. 2005;235:1065–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol. 2005;185:64–71.PubMedGoogle Scholar
  8. 8.
    Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2005;16:765–78.PubMedGoogle Scholar
  9. 9.
    Gillams AR. Thermal ablation of liver metastases. Abdom Imaging. 2001;26:361–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2007;17:684–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Chopra S, Dodd III GD, Chintapalli KN, et al. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual- phase contrast-enhanced CT. AJR Am J Roentgenol. 2001;177:381–7.PubMedGoogle Scholar
  12. 12.
    Hussain S, Reinhold C, Mitchell D. Cirrhosis and lesion characterization at MR Imaging. Radiographics. 2009;29:1637–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for HCC before liver transplantation? No, please don’t. J Hepatol. 2005;43:563–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities – Part I. J Vasc Interv Radiol. 2001;12:1021–32.CrossRefGoogle Scholar
  15. 15.
    Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities – Part II. J Vasc Interv Radiol. 2001;12:1135–48.PubMedCrossRefGoogle Scholar
  16. 16.
    Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology. 2001;221:447–54.PubMedCrossRefGoogle Scholar
  17. 17.
    de Baere T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol. 2003;181:695–700.PubMedGoogle Scholar
  18. 18.
    Veit P, Antoch G, Stergar H, et al. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16:80–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Mazzaferro V, Chun YS, Poon RTP, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;11:693–9.CrossRefGoogle Scholar
  20. 20.
    Dromain C, de Baerre T, Elias D, et al. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology. 2002;223:255–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radiofrequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Rhim H, Yoon KH, Cho Y, et al. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radiographics. 2003;23:123–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Uppot RN, Silverman SG, Zagoria RJ, Tuncali K, Childs DD, Gervais DA. Image-guided percutaneous ablation of renal cell carcinoma: a primer of how we do it. AJR Am J Roentgenol. 2009;192:1558–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zinke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170:2217–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Matin SF, Ahrar K, Cadeddu JA, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol. 2006;176:1973–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Cantwell CP, Wah TM, Gervais DA, et al. Protecting the ureter during radiofrequency ablation of renal cell cancer: a pilot study of retrograde pyeloperfusion with cooled dextrose 5% in water. J Vasc Interv Radiol. 2008;19:1034–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Wah TM, Koenig P, Irving HC, Gervais DA, Mueller PR. Radiofrequency ablation of a central renal tumor: protection of the collecting system with a retrograde cold dextrose pyeloperfusion technique. J Vasc Interv Radiol. 2005;16:1551–5.PubMedGoogle Scholar
  28. 28.
    Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol. 2007;189:429–36.PubMedCrossRefGoogle Scholar
  29. 29.
    Miyakita H, Tukunaga M, Ouda H, et al. Significance of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002;9:15–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Kand GE, White Jr RL, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806–9.CrossRefGoogle Scholar
  31. 31.
    Schirmang TC, Mayo-Smith WW, Dupuy DE, Beland MD, Grand DJ. Kidney neoplasms: renal halo sign after percutaneous radiofrequency ablation – incidence and clinical importance in 101 consecutive patients. Radiology. 2009;253:263–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology. 2003;226:417–24.PubMedCrossRefGoogle Scholar
  33. 33.
    Javadi S, Matin SF, Tamboli P, Ahrar K. Unexpected atypical findings on CT after radiofrequency ablation of small renal-cell carcinoma and the role of percutaneous biopsy. J Vasc Interv Radiol. 2007;18:1186–91.PubMedCrossRefGoogle Scholar
  34. 34.
    Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: part 2, Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol. 2005;185:72–80.PubMedGoogle Scholar
  35. 35.
    Lokken RP, Gervais DA, Arellano RS, et al. Inflammatory nodules mimic applicator track seeding after percutaneous ablation of renal tumors. AJR Am J Roentgenol. 2007;189:845–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Mayo-Smith WW, Dupuy DE, Parikh PM, Pezzullo JA, Cronan JJ. Imaging-guided percutaneous radiofrequency ablation of solid renal masses: techniques and outcomes of 38 treatment sessions in 32 consecutive patients. AJR Am J Roentgenol. 2003;180:1503–8.PubMedGoogle Scholar
  37. 37.
    Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology. 2010;254:301–7.PubMedGoogle Scholar
  38. 38.
    American Cancer Society. Cancer facts and figures 2005. Atlanta, GA: American Cancer Society; 2005.Google Scholar
  39. 39.
    Lanuti M, Sharma A, Digumarthy SR, et al. Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:160–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Soga N, Yamakado K, Gohara H, et al. Percutaneous radiofrequency ablation of unresectable pulmonary metastases from renal cell carcinoma. BJU Int. 2009;104:790–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Morris DL, Glenn D, King J, et al. Radiofrequency ablation (RFA) of pulmonary colorectal metastases. J Clin Oncol. 2004;22:3732.Google Scholar
  42. 42.
    Bojarski JD, Dupuy DE, Mayo-Smith WW. CT imaging findings of pulmonary neoplasms after treatment with radiofrequency ablation: results in 32 tumors. AJR Am J Roentgenol. 2005;185:466–71.PubMedGoogle Scholar
  43. 43.
    Thanos L, Mylona S, Giannoulakos N, et al. Percutaneous radiofrequency ablation of lung tumors in contact with the aorta: dangerous and difficult but efficient: a report of two cases. Cardiovasc Intervent Radiol. 2008;31:1205–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000;48:1015–24.PubMedCrossRefGoogle Scholar
  45. 45.
    Okuma T, Matsuoka T, Yamamota A, et al. Determinants of local progression after computed tomography-guided percutaneous radiofrequency ablation for unresectable lung tumors: 9-year experience in a single institution. Cardiovasc Intervent Radiol. 2010;33(4):787–93.PubMedCrossRefGoogle Scholar
  46. 46.
    Laurent F, Philippe M, Latrabe V, Tunon de Lara M, Marthan R. Pneumothoraces and chest tube placement after CT-guided transthoracic lung biopsy using a coaxial technique: incidence and risk factors. AJR Am J Roentgenol. 1999;172:1049–53.PubMedGoogle Scholar
  47. 47.
    Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities – Part II. J Vasc Interv Radiol. 2001;12:1135–48.PubMedCrossRefGoogle Scholar
  48. 48.
    Okuma T, Matsuoka T, Yamamota A, et al. Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol. 2009;82:989–94.PubMedCrossRefGoogle Scholar
  49. 49.
    Anderson EM, Lees WR, Gillams AR. Early indicators of treatment success after percutaneous radiofrequency of pulmonary tumors. Cardiovasc Intervent Radiol. 2009;32:478–83.PubMedCrossRefGoogle Scholar
  50. 50.
    Steinke K, King J, Glenn D, Morris DL. Pulmonary hemorrhage during percutaneous radiofrequency ablation: a more frequent complication than assumed? Interact Cardiovasc Thorac Surg. 2003;2:462–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Haga H, Saito T, Okumoto K, et al. Successful percutaneous radiofrequency ablation of adrenal metastasis from hepatocellular carcinoma. J Gastroenterol. 2005;40:1075–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Spieza S, Garbepglio R, Milone F, et al. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid. 2009;19:219–25.CrossRefGoogle Scholar
  53. 53.
    Kinoshita T, Iwamoto E, Tsuda H, Seki K. Radiofrequency ablation as local therapy for early breast carcinomas. Breast Cancer. 2011;18(1):10–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of RadiologyMassachusetts General HospitalBostonUSA

Personalised recommendations